First major milestone met in trial to inform neoadjuvant targeted therapy options for patients with early-stage lung cancer

NEW YORK, NY (October 24, 2023) – The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER), examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.

This is the first of the LEADER trial’s major milestones to be met, with many more to come. Seventeen sites are currently enrolling patients in the study with more sites expected to join the trial.

The LEADER trial, together with matched industry-sponsored therapeutic trials, aims to develop data that will support oncologists in their targeted treatment planning for cancer patients prior to surgery by screening for eleven actionable driver mutations in patients.

“We’re incredibly excited to have met this first major milestone in patient accrual. The importance of this study to patients with early-stage lung cancers cannot be overstated. Expanding the benefit of targeted treatment to this group can have a marked impact on patient care,” says Mark G. Kris, MD, Attending Physician, Thoracic Oncology Service, Department of Medicine at Memorial Sloan Kettering Cancer Center and one of the investigators of the LEADER trial.

Patients with early-stage lung cancers who are interested in participating in the LCMC LEADER trial should discuss the study with their oncologist to determine eligibility and the process for enrollment.

To learn more about LCRF and its grants program, visit

To learn more about LCMC and the LEADER trial, visit


About the Lung Cancer Research Foundation (LCRF)
The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 409 research grants, totaling nearly $42 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information, visit